The DREAM (Diabetes Reduction Assessment With Ramipril and Rosiglitazone Medication) Trial
This study has been completed.
Sponsor:
Gerstein, Hertzel, MD
Collaborators:
Canadian Institutes of Health Research (CIHR)
Aventis Pharmaceuticals
GlaxoSmithKline
King Pharmaceuticals is now a wholly owned subsidiary of Pfizer
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
Gerstein, Hertzel, MD
ClinicalTrials.gov Identifier:
NCT00095654
First received: November 5, 2004
Last updated: November 9, 2009
Last verified: November 2009
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Study Status: | This study has been completed. |
|---|---|
| Study Completion Date: | October 2006 |
| Estimated Primary Completion Date: | No date given |
Publications:
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):